CTLA4 and cancer: In addition, the overexpression of immune checkpoints and the loss of anti-immune checkpoint molecules are regarded as significant mechanisms resulting in immune escape of tumours, thus cancer checkpoint inhibitors, such as anti-PD1, anti-CTLA4, and anti-PDL1 are widely used in cancer treatments [97,98].